Financing ·
USANA amends credit agreement to raise asset sale limit and set $100M EBITDA covenant
USNAUsana Health Sciences Inc
On September 30, 2026, USANA Health Sciences entered into a First Amendment to its Third Amended and Restated Credit Agreement with Bank of America. The amendment raises the annual general asset sale basket limit from $500,000 to $2,500,000 and permits the sale of real property in Sydney, Australia. It also establishes a minimum Consolidated EBITDA covenant of $100 million for trailing four-fiscal-quarter periods beginning with the quarter ending October 3, 2026, reducing this threshold to $70 million if revolving exposure is $50 million or less. The company reaffirmed its obligations and confirmed no defaults exist under the loan documents. USANA Health Sciences manufactures and sells nutritional supplements, skin care products, and personal care items.